Fresenius Se & Co. Kgaa · XETR:FRE

Fresenius Se & Co. Kgaa — Fresenius Medical Care — FY2007 Earnings Presentation

18 slides from Fresenius Se & Co. Kgaa's earnings presentation, Feb 20, 2008

  1. Slide 1: Fresenius Medical Care: The World's Leading Renal Therapy Company

    Fresenius Medical Care The World’s Leading Renal Therapy Company Full Year 2007 Results Press conference, February 20, 2008

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation includes certain forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory

  3. Slide 3: FY 2007 – Another Record Year

    FY 2007 – Another Record Year (excluding one-time items in 2006) Guidance FY 2007 Growth Revenue > $ 9,500 m $ 9,720 m +14% Operating Income $ 1,580 m +20% Net income $ 685-705 m $ 717 m +25% Exceeded the Upper End of Guidance Business Update Press Conference, February 20, 2008 © 2008 Fresenius Medi

  4. Slide 4: 11th Consecutive Dividend Increase Proposed

    11th Consecutive Dividend Increase Proposed In € per share 0.60 0.54 CAGR 97-07 = 12% 0.47 0.41 0.40 0.37 0.34 0.31 0.28 0.26 0.23 0.20 0.20 0.17 0.00 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Ordinary shares +15% CAGR = Cumulative Average Growth Rate Business Update Press Conference, F

  5. Slide 5: FY 2007 – Strong Revenue Growth

    FY 2007 – Strong Revenue Growth Total Revenue Increased 14% to $ 9,720 m * In % of total revenue: North America 69% Europe 22% Asia-Pacific 5% Latin America 4% North America Europe $ 6,663 m $ 2,116 m + 11% + 20% / + 9% cc 5% organic growth Asia-Pacific $ 541 m + 44% / + 40% cc Latin America $ 400 m

  6. Slide 6: Dialysis Services - Global

    Dialysis Services - Global Strong Overall Revenue Growth $ in millions FY 2006 FY 2007 Growth cc 1) North America 5,353 5,962 11% International 913 1,211 33% 23% 1) Total 6,266 7,173 14% 13% X Continued strong growth in Europe of 12%cc (11% organic), Latin America with 14%cc (14% organic) and Asia-P

  7. Slide 7: World Leader in Services

    World Leader in Services Company No of patients Company estimates X Europe (EU) North Fresenius Medical Care 121,431 America DaVita 107,000 X Asia-Pacific (AP) Dialysis Clinic Inc. 13,000 - Fresenius Medical Care 26,902 Kuratorium für Heimdialyse 18,000 Europe Diaverum 10,000 B.Braun 6,200 Patienten

  8. Slide 8: Payment for dialysis in Europe

    Payment for dialysis in Europe There is an evolution towards an increased bundling of products and services Recent Examples: 2007: Transportation included in the reimbursement rate in Romania 2007: EPO included in the reimbursement rate in Hungary 2008: Pharmaceuticals and labs included in the reimb

  9. Slide 9: Case Study: Portugal

    Case Study: Portugal “Comprehensive Reimbursement Model” ¾ Integrated and quality-driven approach ¾ Reimbursement rate to increase by about 50% ¾ Includes all necessary dialysis services, dialysis products, lab services renal drug administration and others ¾ Directly depend on the fulfillment of cer

  10. Slide 10: Dialysis Products - Global

    Dialysis Products - Global Continued Excellent Growth $ in millions FY 2006 FY 2007 Growth cc Total revenue 2,773 3,278 18% 12% (incl. Internal Revenue) External revenue 2,122 2,507 18% 12% North America 561 661 18% 18% International 1,560 1,846 18% 10% cc = constant currency Business Update Press C

  11. Slide 11: Cash Flow

    Cash Flow $ in millions FY 2006 FY 2007 Growth Net cash provided by operating activities 1,106 1,200 9% 12.3% of revenue Capital expenditures (net) (450) (549) Free Cash Flow 656 651 Acquisitions, net of divestitures (159) (228) Free Cash Flow after acquisitions 497 423 Free Cash Flow after acquisit

  12. Slide 12: Debt / EBITDA Development

    Debt / EBITDA Development De-leveraging ahead of schedule Debt / EBITDA Development 4.0 3.81cl 3.5 3.23 3.09 Target 3.0 2007 2.76 2.84 Target 2.5 mid-term 2.26 2.0 1.82 2002 2003 2004 2005 2006 2007 Year end cl = closing RCG Financials Press Conference, February 20, 2008 © 2008 Fresenius Medical Car

  13. Slide 13: Summary – 2008 Growth Drivers

    Summary – 2008 Growth Drivers North Asia- America Europe Pacific Renal Pharma 9 9 Expansion of Clinic Network 9 9 9 Reimbursement Based on Quality 9 9 9 Increased Product Market Share 9 9 Targeted Revenue Growth >7% Business Update Press Conference, February 20, 2008 © 2008 Fresenius Medical Care AG

  14. Slide 14: Outlook 2008

    Outlook 2008 $ in millions Guidance Net Revenues > $10,400 Net Income $805 - 825 Leverage ratio (Debt/EBITDA) < 2.8 Capital Expenditure ~ $650 - 750 Acquisitions ~ $150 - 250 X Another strong year ahead X Increased investment budget driven by further growth opportunities Outlook 2008 Press Conferenc

  15. Slide 15: 2010 Revenue Target

    2010 Revenue Target Revenue $ in billions 13 > $11.5 11 $9.7 9 Achieved original target $8.5 issued in 2005 of > $10.0 billion nearly 3 years ahead of time 7 $6.8 2005 2006 2007 2010 Sustainable Growth of Earnings After Tax of Low to Mid-Teens per Year Outlook 2010 Press Conference, February 20, 200

  16. Slide 16: Thank You for your interest in Fresenius Medical Care!

    Thank You for your interest in Fresenius Medical Care ! Press Conference, February 20, 2008 © 2008 Fresenius Medical Care AG & Co. KGaA 16

  17. Slide 17: Fresenius Medical Care

    Fresenius Medical Care The World’s Leading Renal Therapy Company Full Year 2007 Results Press conference, February 20, 2008 Press Conference, February 20, 2008 © 2008 Fresenius Medical Care AG & Co. KGaA

  18. Slide 18: Q&A Session

    Q&A Session Press Conference, February 20, 2008 © 2008 Fresenius Medical Care AG & Co. KGaA 18

Fresenius Medical Care — FY2007 Earnings Presentation on 6ix